January 01, 2019


January 01, 2019

Rashmi Dalai


Rashmi started her career on Wall Street with time spent in both convertible bonds sales and trading at Goldman Sachs and structured derivative products at Lehman Brothers. She left to form her own healthcare consulting practice, and spent over a decade advising a wide range of clients from large university hospitals to start-ups on business and financial strategies. Her role included taking interim COO and CFO positions for clients managing periods of high growth or other business transitions.

In 2007, she began splitting her time between the US and Asia (China, Indonesia, and Singapore) and expanded her consulting business to include advisory on business communications strategies and global thought leadership. Prior to joining The Economist Group, she was Head of Strategic Planning at Weber Shandwick, a global communications and PR firm, in Singapore.

Rashmi holds a Bachelors in International Affairs from Johns Hopkins University and a Masters in International Affairs from Columbia University with a concentration in International Finance and Banking. 


中国、オーストラリア、香港、日本、シンガポール、韓国、台湾、タイの8か国の調査では、虚血性心疾患 (IHD) および脳卒中の直接的・間接的費用のうち、喫煙、高血圧、肥満、高コレステロールの4つの改善可能な危険因子によるものが530億ドルと推定されている。



こうした関係機関の決定と戦略を報告するために、ザ・エコノミスト・インテリジェンス・ユニット(The Economist Intelligence Unit/EIU) とその子会社であるEIU Healthcareは、中国、オーストラリア、香港、日本、シンガポール、韓国、台湾、およびタイのアジア市場において、改善可能な四大循環器疾患危険因子に関する蔓延状況とコストの調査を実施した。

Enjoy in-depth insights and expert analysis - subscribe to our Perspectives newsletter, delivered every week